⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887631 | 0.73 | NPC1 (0.41) | — | |
| SCHEMBL20570053 | 0.72 | TRPM8 (0.34) | — | |
| SCHEMBL5151745 | 0.69 | NPC1 (0.32) | — | |
| SCHEMBL2854030 | 0.69 | NOTUM (0.32) | — | |
| Bromide SCHEMBL7429002 | 0.68 | NPC1 (0.32) | — | |
| SCHEMBL148063 | 0.68 | — | — | |
| SCHEMBL15063186 | 0.68 | MAP4K1 (0.31) | — | |
| Water SCHEMBL29953274 | 0.66 | NOTUM (0.39) | — | |
| Zinc Ion SCHEMBL14482007 | 0.65 | — | — | |
| SCHEMBL19603001 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685762-B2 | Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof | SD Chem, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11667665-B2 | Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof | SD Chem, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| EP-3920936-A1 | AQUEOUS SUSPENSION COMPOSITIONS, FORMULATIONS, AND WATER DISPERSIBLE DRY COMPOSITIONS COMPRISING 16ALPHA-BROMO-3BETA-HYDROXY-5ALPHA-ANDROSTAN-17-KETONE AND HYDRATES, DERIVATIVES, AND ANALOGS THEREOF | SD Chem, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20210061847-A1 | AQUEOUS SUSPENSION COMPOSITIONS, FORMULATIONS, AND WATER DISPERSIBLE DRY COMPOSITIONS COMPRISING 16ALPHA-BROMO-3BETA-HYDROXY-5ALPHA-ANDROSTAN-17-KETONE AND HYDRATES, DERIVATIVES, AND ANALOGS THEREOF | SD Chem, Inc. | 2021-03-04 | — | — | US | disclosed |
| US-20210061846-A1 | AQUEOUS SUSPENSION COMPOSITIONS, FORMULATIONS, AND WATER DISPERSIBLE DRY COMPOSITIONS COMPRISING 16ALPHA-BROMO-3BETA-HYDROXY-5ALPHA-ANDROSTAN-17-KETONE AND HYDRATES, DERIVATIVES, AND ANALOGS THEREOF | SD Chem, Inc. | 2021-03-04 | — | — | US | disclosed |
| US-10836788-B2 | Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof | SD Chem, Inc. (US) | 2020-11-17 | — | — | US | disclosed |
| WO-2020163026-A1 | AQUEOUS SUSPENSION COMPOSITIONS, FORMULATIONS, AND WATER DISPERSIBLE DRY COMPOSITIONS COMPRISING 16ALPHA-BROMO-3BETA-HYDROXY-5ALPHA-ANDROSTAN-17-KETONE AND HYDRATES, DERIVATIVES, AND ANALOGS THEREOF | SD Chem, Inc. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247838-A1 | AQUEOUS SUSPENSION COMPOSITIONS, FORMULATIONS, AND WATER DISPERSIBLE DRY COMPOSITIONS COMPRISING 16ALPHA-BROMO-3BETA-HYDROXY-5ALPHA-ANDROSTAN-17-KETONE AND HYDRATES, DERIVATIVES, AND ANALOGS THEREOF | SD Chem, Inc. | 2020-08-06 | — | — | US | disclosed |
| US-8541600-B2 | 11-aza, 11-thia and 11-oxa sterol compounds and compositions | Harbor Therapeutics, Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | BIOVIE INC. | 2012-04-26 | — | — | US | disclosed |
| US-6548488-B2 | Treatment of solid tumors, breast cancer | AVENTIS PHARMA S.A. (FR) | 2003-04-15 | — | — | US | disclosed |
| US-20030060425-A1 | Immune modulation method using steroid compounds | BIOVIE INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2003006029-A1 | METHOD OF INDUCING APOPTOSIS IN CANCER CELLS | THE UNIVERSITY OF SYDNEY (AU) | 2003-01-23 | — | — | WO | disclosed |
| EP-1267873-A2 | A COMPOSITION COMPRISING CAMPTOTHECIN OR A CAMPTOTHECIN DERIVATIVE AND AN ALKYLATING AGENT FOR THE TREATMENT OF CANCER | Aventis Pharma S.A. (FR) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002069977-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20010056082-A1 | Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer | PFIZER ENTERPRISES SARL (LU) | 2001-12-27 | — | — | US | disclosed |
| WO-2001068066-A2 | A COMPOSITION COMPRISING CAMPTOTHECIN OR A CAMPTOTHECIN DERIVATIVE AND AN ALKYLATING AGENT FOR THE TREATMENT OF CANCER | AVENTIS PHARMA S.A. (FR) | 2001-09-20 | — | — | WO | disclosed |
| US-5840673-A | Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of p53-related tumors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0871475-A2 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3 (IGF-BP3) IN TREATMENT OF P53-RELATED TUMORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997009998-A2 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3 (IGF-BP3) IN TREATMENT OF P53-RELATED TUMORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-03-20 | — | — | WO | disclosed |